-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Metacrine, Inc gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US59101E1038 |
| Sector | |
| Industry |
| Beta | -0.74 |
|---|---|
| Market Cap | 25M |
| PE Ratio | None |
| Target Price | 0.5 |
| Dividend Yield | None |
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MTCR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
